Comparative Pharmacology
Head-to-head clinical analysis: INVAGESIC versus ROXICET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INVAGESIC versus ROXICET.
INVAGESIC vs ROXICET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
INVAGESIC is a combination of pregabalin, an alpha2-delta ligand that inhibits presynaptic calcium channels to reduce excitatory neurotransmitter release, and meloxicam, a COX-2 selective NSAID that decreases prostaglandin synthesis via cyclooxygenase inhibition.
Roxicet is a combination of oxycodone, a full mu-opioid receptor agonist, and acetaminophen, which inhibits cyclooxygenase (COX) enzymes, primarily in the central nervous system, to reduce pain perception and fever.
Adults: 1-2 tablets (325 mg acetaminophen/5 mg hydrocodone) orally every 4-6 hours as needed for pain, not to exceed 12 tablets per day.
1-2 tablets (oxycodone 5-10 mg/acetaminophen 325-650 mg) orally every 4-6 hours as needed for pain; maximum acetaminophen 4000 mg/day (3000 mg/day in high-risk patients).
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in adults; prolonged to 8-12 hours in elderly or mild renal impairment
Oxycodone: 3-5 hours (immediate-release); prolonged in hepatic/renal impairment. Acetaminophen: 2-3 hours.
Renal: ~70% as unchanged drug; biliary/fecal: ~30% as metabolites
Primarily renal (90% as glucuronide conjugates, <10% unchanged). Biliary/fecal excretion is minor (<5%).
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination